Targeted molecular therapies that disrupt specific intracellular signaling pathways are increasingly used for the treatment of cancer. The rationale for this approach is based on our increasing understanding of the genes that are causally implicated in cancer and the clinical observation that the genetic features of a cancer can be predictive of patient response to targeted therapies. The goal of our project is to discover new cancer biomarkers that define subsets of drug-sensitive patients. Towards this aim we are screening a range of anti-cancer therapeutics against a large number of genetically characterized human cancer cell lines and correlating drug sensitivity with extensive genetic data. This information can be used to inform the optimal clinical application of cancer drugs as well as the design of clinical trials of investigational compounds being developed for the clinic [more]

Interested in receiving 'Genomics of Drug Sensitivity in Cancer' news and release information? Then sign up [here]

Upcoming screening compounds: Metformin, AICAR, Cisplatin and Axitinib